Skip to content

Guidelines

TL;DR — The major guidelines catalogued here converge on SSRIs/SNRIs and CBT as first-line options, with patient preference helping to choose between them (Bandelow 2023, PMID 35900161; Katzman 2014, PMID 25081580; Baldwin 2014, PMID 24713617; revised German S3: Bandelow 2022, PMID 34609587). They disagree on benzodiazepine restriction, where pregabalin and quetiapine sit, screening asymptomatic adults, and continuation duration. WFSBP Version 3 evaluated 1,007 RCTs with 33 experts from 22 countries (Bandelow 2023, PMID 35900161). NICE CG113 was published in 2011 and last updated in 2020 (live page checked 2026-09-02). The USPSTF recommends adult screening but finds evidence insufficient at age ≥65; its evidence report found no trial showing that screening itself improves outcomes (PMIDs: 37338866, 37338868). A PubMed search rerun on 2026-09-02 found no current APA GAD practice guideline; the 1998 anxiety guideline concerns panic disorder (PMID 9585731). The document catalogue is in literature/guidelines/REGISTRY.md.

What they agree on

Recommendation Bodies
SSRIs and SNRIs are first-line medication WFSBP (Bandelow 2023, PMID 35900161); BAP (Baldwin 2014, PMID 24713617); German S3 (Bandelow 2014, PMID 25138725); Canadian (Katzman 2014, PMID 25081580); Brazilian (Baldaçara 2024, PMID 37956131); Harvard South Shore late-life algorithm (Chen 2025, PMID 39352792)
CBT is the first-line psychotherapy WFSBP (Bandelow 2023, PMID 35900161); German S3 — "supported by higher-level evidence than any other psychotherapeutic technique" (Bandelow 2014, PMID 25138725); Brazilian, specifying individual third-wave CBT (Baldaçara 2024, PMID 37956131); AACAP for children (Walter 2020, PMID 32439401)
Patient preference decides between modalities German S3 (Bandelow 2014, PMID 25138725); echoed by the treatment meta-analysis that found drug pre-post effects larger but recommended leaving the choice to the patient (Bandelow 2015, PMID 25932596)
Switch modality if the first fails German S3: switch to the other form or combine (Bandelow 2014, PMID 25138725); WFSBP makes explicit recommendations for non-responders (Bandelow 2023, PMID 35900161)
Guidelines should also say what not to use WFSBP Version 3 explicitly "made recommendations against interventions with insufficient evidence" (Bandelow 2023, PMID 35900161)

Two quantitative anchors that guidelines repeat: initial-treatment response is 45–65% (German S3; Bandelow 2014, PMID 25138725), and CBT response in published GAD studies is 47–75% versus 44–81% for drug treatment (Bandelow 2013, PMID 23671484).

Where they diverge

Issue Positions Source
Benzodiazepines German S3/Bandelow: effective short-term but should not be given long-term because of addiction risk (Bandelow 2013, PMID 23671484). Brazilian guideline lists benzodiazepines among indicated treatments alongside antidepressants and pregabalin (Baldaçara 2024, PMID 37956131). Harvard South Shore late-life algorithm: caution with benzodiazepines and hydroxyzine, with periodic benefit–harm review for patients started decades earlier (Chen 2025, PMID 39352792). The benzodiazepine-specific network meta-analysis finds them efficacious with a favourable safety profile (Fernandes 2025, PMID 40544830) Unresolved; the disagreement tracks whether the outcome measured is trial dropout or long-term dependence
Pregabalin Second-line in most guidelines; a 2025 meta-analysis of 14 studies/4,822 patients argues for first-line status on efficacy, tolerability and cost-effectiveness (Cardoner 2025, PMID 39989902) Contested
Quetiapine / atypical antipsychotics Studied and listed in the Brazilian guideline (Baldaçara 2024, PMID 37956131); the largest mean HAM-A estimate in one network but poorly tolerated (Slee 2019, PMID 30712879); umbrella review finds no high-quality antipsychotic evidence in anxiety outside quetiapine in GAD (Garakani 2024, PMID 38382649) Evidence and positioning remain contested; harms restrict use
Screening asymptomatic adults USPSTF: screen adults including pregnant/postpartum (B); insufficient evidence ≥65 (I) (USPSTF 2023, PMID 37338866). USPSTF: screen children 8–18 (B); insufficient ≤7 (I) (USPSTF 2022, PMID 36219403). Published objection to the late-life I statement (Andreescu 2023, PMID 36652241) The B recommendation rests on instrument accuracy plus treatment efficacy, not on screening trials (O'Connor 2023, PMID 37338868)
Treatment duration after remission German S3: continue drug treatment 6–12 months after remission (Bandelow 2014, PMID 25138725). Relapse-prevention trials ran 24–76 weeks (escitalopram) and 26 weeks (duloxetine, agomelatine) and all favoured continuation (Allgulander 2006, PMID 16316482; Davidson 2008, PMID 18559291; Stein 2012, PMID 22901350) Guideline duration is shorter than the longest positive trials; no guideline addresses indefinite treatment
Psychodynamic therapy German S3 recommends it as second-line (Bandelow 2014, PMID 25138725), supported by GAD-specific RCT evidence showing HAM-A equivalence with CBT but CBT superiority on worry and trait anxiety (Leichsenring 2009, PMID 19570931; Salzer 2011, PMID 21878162) Position varies by country
Nutraceuticals and phytoceuticals Given a dedicated international guideline graded Recommended → Not Recommended (Sarris 2022, PMID 35311615); largely absent from mainstream GAD guidelines despite silexan's measured effect (Zhang 2022, PMID 35378276; Müller 2026, PMID 40788541) Parallel guideline stream

The stepped-care model

NICE's structure is stepped care, and it is the model most other health systems have adapted — a Spanish guideline built with the ADAPTE method took 47 of its 49 recommendations directly from the 2011 NICE GAD guidance, adapting seven and excluding three (Hurtado 2020, PMID 32427320). That is an unusually explicit demonstration of how much of the world's GAD guidance is one document in translation.

The evidence for the low-intensity steps has since been meta-analysed specifically: low-intensity CBT for GAD has its own efficacy meta-analysis (Powell 2024, PMID 38166836), and the collaborative-care trials give the strongest system-level effect sizes in the condition (Roy-Byrne 2010, PMID 20483968; Craske 2011, PMID 21464362) — see comorbidity and primary care.

Population-specific guidance

Population Guidance Source
Children and adolescents CBT and SSRIs both have considerable empirical support as safe and effective short-term treatments; SNRIs have some support; research priority is convenient, efficient, cost-effective delivery given a "protracted severe shortage" of child-trained specialists AACAP (Walter 2020, PMID 32439401)
Children and adolescents (screening) Screen ages 8–18 (B); insufficient ≤7 USPSTF 2022, PMID 36219403
Perinatal Comprehensive question-and-answer guideline across case identification, care organisation, non-pharmacological, pharmacological, neuromodulation and complementary interventions, high-risk situations, and the father/co-parent's mental health; medication safety evidence prioritised from large observational studies because RCT data are absent CANMAT perinatal (Vigod 2025, PMID 39936923)
Older adults Stepwise algorithm: SSRI (sertraline/escitalopram) → different SSRI or venlafaxine/duloxetine → pregabalin/gabapentin, lavender oil, agomelatine → quetiapine; caution with benzodiazepines and hydroxyzine Harvard South Shore (Chen 2025, PMID 39352792)
Comorbid mood and anxiety CANMAT task force recommendations for mood disorders with comorbid anxiety Schaffer 2012, PMID 22303519
Nutraceuticals/phytoceuticals WFSBP/CANMAT taskforce, 31 academics, 15 countries Sarris 2022, PMID 35311615

Does guideline-concordant care produce better outcomes?

This is the question guidelines are least often asked, and the answer from the largest naturalistic dataset is uncomfortable.

Study Design Finding
Prins 2010 (PMID 20049547) 721 patients with current DSM-IV anxiety or depressive disorder recruited from 67 Dutch GPs (NESDA); guideline concordance judged against Dutch College of General Practitioners criteria from electronic medical records 39% received guideline-concordant care. In multivariate models, clinical need factors dropped out; what remained were perceived need for medication (OR 2.99, 1.84–4.85), counselling (OR 2.25, 1.29–3.95), referral (OR 1.83, 1.09–3.09) and positive evaluation of access (OR 1.31, 1.05–1.65); low educational level reduced the odds (OR 0.33, 0.11–0.98)
Prins 2011 (PMID 22099636) Same cohort followed 12 months Patients receiving guideline-concordant care had more severe symptoms at baseline yet equal improvement at 12 months; the particular type of treatment made no difference to clinical outcome. The authors state plainly that "the added value of guideline concordant care could not be demonstrated"
Prins 2011 (PMID 20586845) Cost analysis in 568 patients from the same cohort Guideline adherence was significantly associated with increased care use and costs, while fully met perceived need was unrelated to costs
Castro-Rodríguez 2015 (PMID 25451451) 212 patients across three primary-care and one specialist centre in Barcelona; medical-record diagnoses against MINI Sensitivity for depression 0.49 in primary care vs 0.75 in specialist care (adjusted OR 17.34, 4.73–63.61); treatment adequacy 80.6% vs 94.4% (adjusted OR 8.11, 1.39–47.34); detection of anxious comorbidity in depressed patients was only 50% even in specialist care

Three readings are possible and none has been excluded. Guideline-concordant care may be correctly targeted at more severe patients and therefore look no better on unadjusted follow-up (confounding by indication). The guidelines may recommend treatments whose real-world effect is smaller than trial estimates. Or concordance as measured from medical records may not capture what actually matters — continuity, validation, persistence — which is what patients name (patient experience and advocacy) and what collaborative care operationalises (comorbidity and primary care).

What the data do establish is that concordance is patterned by education and by patients' own perceived need rather than by clinical severity (Prins 2010, PMID 20049547) — an equity finding that no guideline in the registry addresses.

What the guidelines cannot answer

  1. What works for GAD without comorbid depression, because the trials they synthesise either exclude comorbidity or allow all of it (comorbidity and primary care).
  2. Whether to treat indefinitely. Guidance stops at 6–12 months post-remission (Bandelow 2014, PMID 25138725) against a disorder with 0.38 five-year remission probability in clinic cohorts (Yonkers 2000, PMID 10974960).
  3. Whether screening helps. A B recommendation issued without a positive screening trial (USPSTF 2023, PMID 37338866; O'Connor 2023, PMID 37338868).
  4. How to implement treatment-resistance criteria in GAD. A trans-anxiety Delphi consensus now provides 14 recommendations and a potential staging framework, but GAD-specific validation and adoption remain open (Domschke 2024, PMID 38214637; treatment-resistant GAD).
  5. Whether following them improves outcomes. The one cohort designed to test this could not demonstrate added value, while showing higher costs (Prins 2011, PMID 22099636; Prins 2011, PMID 20586845).
  6. Whether the diagnosis they treat is the right one. No guideline engages with the published proposal to drop the excessiveness criterion (Ruscio 2024, PMID 39364896) — see the diagnostic boundary.

Open questions

  • Why is there no current APA practice guideline for GAD, when APA guidelines exist for other common disorders? (Verified absent on PubMed search, 2026-09-02; the 1998 anxiety guideline addresses panic disorder — PMID 9585731.)
  • Should benzodiazepine restriction be relaxed given the within-class network's favourable safety findings (Fernandes 2025, PMID 40544830), or maintained on dependence grounds that trials do not measure?
  • Is pregabalin first-line? One meta-analysis says yes (Cardoner 2025, PMID 39989902); no guideline in this build agrees.
  • How much of global GAD guidance is downstream of NICE CG113? The Spanish ADAPTE exercise suggests a great deal (Hurtado 2020, PMID 32427320); nobody has mapped the dependency graph.
  • Why is guideline-concordant care associated with equal outcomes and higher costs (Prins 2011, PMID 22099636; Prins 2011, PMID 20586845)? Confounding by indication, over-estimated trial effects and mismeasured concordance are all untested explanations.
  • Why is concordance patterned by education level rather than clinical need (Prins 2010, PMID 20049547), and does any guideline address that?
  • Should guidelines recommend continuation beyond 12 months? A PubMed search rerun on 2026-09-02 located relapse-prevention trials but no GAD trial directly comparing fixed-duration with indefinite continuation using a defined taper; this remains a dated evidence gap.

References

  1. Bandelow B, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders — Version 3. Part I: Anxiety disorders. World J Biol Psychiatry. 2023;24:79-117. PMID 35900161
  2. Bandelow B, et al. WFSBP guidelines … Version 3. Part II: OCD and PTSD. World J Biol Psychiatry. 2023;24:118-134. PMID 35900217
  3. Katzman MA, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14 Suppl 1:S1. PMID 25081580
  4. Baldwin DS, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:403-39. PMID 24713617
  5. Bandelow B, et al. The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int. 2014;111:473-80. PMID 25138725
  6. Bandelow B, et al. The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int. 2013;110:300-9. PMID 23671484
  7. Kendall T, et al. Management of generalised anxiety disorder in adults: summary of NICE guidance. BMJ. 2011;342:c7460. PMID 21270081
  8. NICE. Generalised anxiety disorder and panic disorder in adults: management (CG113). Published 26 January 2011; last updated 15 June 2020. https://www.nice.org.uk/guidance/cg113 (accessed 2026-09-02)
  9. Hurtado MM, et al. Development of a guideline for the treatment of generalized anxiety disorder with the ADAPTE method. Int J Qual Health Care. 2020;32:356-363. PMID 32427320
  10. Baldaçara L, et al. Brazilian Psychiatric Association treatment guidelines for generalized anxiety disorder: perspectives on pharmacological and psychotherapeutic approaches. Braz J Psychiatry. 2024;46:e20233235. PMID 37956131
  11. Walter HJ, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry. 2020;59:1107-1124. PMID 32439401
  12. Vigod SN, et al. Canadian Network for Mood and Anxiety Treatments 2024 Clinical Practice Guideline for the Management of Perinatal Mood, Anxiety, and Related Disorders. Can J Psychiatry. 2025;70:429-489. PMID 39936923
  13. Schaffer A, et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012;24:6-22. PMID 22303519
  14. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51:9S-91S. PMID 16933543
  15. Sarris J, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The WFSBP and CANMAT Taskforce. World J Biol Psychiatry. 2022;23:424-455. PMID 35311615
  16. Chen A, et al. A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient. J Geriatr Psychiatry Neurol. 2025;38:155-171. PMID 39352792
  17. US Preventive Services Task Force. Screening for Anxiety Disorders in Adults. JAMA. 2023;329:2163-2170. PMID 37338866
  18. US Preventive Services Task Force. Screening for Anxiety in Children and Adolescents. JAMA. 2022;328:1438-1444. PMID 36219403
  19. O'Connor EA, et al. Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023;329:2171-2184. PMID 37338868
  20. Andreescu C, et al. Is Anxiety in Late Life an Uncharted Territory? JAMA Psychiatry. 2023;80:197-198. PMID 36652241
  21. American Psychiatric Association Work Group on Panic Disorder. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry. 1998;155:1-34. PMID 9585731
  22. Slee A, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393:768-777. PMID 30712879
  23. Fernandes H, et al. Comparative Efficacy and Safety of Benzodiazepines in the Treatment of Patients with Generalized Anxiety Disorder. Psychother Psychosom. 2025;94:373-388. PMID 40544830
  24. Cardoner N, et al. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? Front Pharmacol. 2025;16:1483770. PMID 39989902
  25. Garakani A, et al. Antipsychotic agents in anxiety disorders: An umbrella review. Acta Psychiatr Scand. 2024;149:295-312. PMID 38382649
  26. Bandelow B, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30:183-92. PMID 25932596
  27. Allgulander C, et al. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006;9:495-505. PMID 16316482
  28. Davidson JR, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder. Eur Neuropsychopharmacol. 2008;18:673-81. PMID 18559291
  29. Stein DJ, et al. Agomelatine prevents relapse in generalized anxiety disorder. J Clin Psychiatry. 2012;73:1002-8. PMID 22901350
  30. Leichsenring F, et al. Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry. 2009;166:875-81. PMID 19570931
  31. Salzer S, et al. Long-term effects of short-term psychodynamic psychotherapy and cognitive-behavioural therapy in generalized anxiety disorder: 12-month follow-up. Can J Psychiatry. 2011;56:503-8. PMID 21878162
  32. Powell CLYM, et al. A meta-analysis on the efficacy of low-intensity cognitive behavioural therapy for generalised anxiety disorder. BMC Psychiatry. 2024;24:10. PMID 38166836
  33. Roy-Byrne P, et al. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010;303:1921-8. PMID 20483968
  34. Craske MG, et al. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry. 2011;68:378-88. PMID 21464362
  35. Zhang W, et al. Medicinal herbs for the treatment of anxiety: A systematic review and network meta-analysis. Pharmacol Res. 2022;179:106204. PMID 35378276
  36. Müller TJ, et al. Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci. 2026;276:1879-1894. PMID 40788541
  37. Ruscio AM, et al. The case for eliminating excessive worry as a requirement for generalized anxiety disorder. Psychol Med. 2024;54:3447-3458. PMID 39364896
  38. Yonkers KA, et al. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-9. PMID 10974960
  39. Prins MA, et al. Patient factors associated with guideline-concordant treatment of anxiety and depression in primary care. J Gen Intern Med. 2010;25:648-55. PMID 20049547
  40. Prins MA, et al. Outcomes for depression and anxiety in primary care and details of treatment: a naturalistic longitudinal study. BMC Psychiatry. 2011;11:180. PMID 22099636
  41. Prins M, et al. The costs of guideline-concordant care and of care according to patients' needs in anxiety and depression. J Eval Clin Pract. 2011;17:537-46. PMID 20586845
  42. Castro-Rodríguez JI, et al. Diagnostic accuracy and adequacy of treatment of depressive and anxiety disorders: A comparison of primary care and specialized care patients. J Affect Disord. 2015;172:462-71. PMID 25451451
  43. Bandelow B, et al. The German Guidelines for the treatment of anxiety disorders: first revision. Eur Arch Psychiatry Clin Neurosci. 2022;272:571-582. PMID 34609587
  44. Domschke K, et al. The definition of treatment resistance in anxiety disorders: a Delphi method-based consensus guideline. World Psychiatry. 2024;23:113-123. PMID 38214637